The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | BELLWAVE-001: nemtabrutinib in patients with R/R CLL/SLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, shares the results of a Phase I study of nemtabrutinib, a non-covalent BTK inhibitor in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; NCT03162536). Whilst the initial results appear promising, with high response rates, a longer follow-up is required to evaluate the durability of response to this drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
